Good practices for 89Zr radiopharmaceutical production and quality control

作者：Thomas Erik Wuensche, Serge K. Lyashchenko, Guus A.M.S. van Dongen, Daniëlle J. Vugts · 发表于：EJNMMI Radiopharmacy and Chemistry · 年份：2024 · DOI：10.1186/s41181-024-00258-y · 被引用次数：32 · 研究领域：Radiopharmaceutical Chemistry and Applications、Orthopaedic implants and arthroplasty、Orthopedic Infections and Treatments

Abstract Background During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due to its advantageous physical properties that allow straightforward radiolabeling of antibodies ( 89 Zr-immuno-PET). The extended half-life of 78.4 h permits flexibility with respect to the logistics of tracer production, transportation, and imaging and allows imaging at later points in time. Additionally, its relatively low positron energy contributes to high-sensitivity, high-resolution PET imaging. Considering the growing interest in radiolabeling antibodies, antibody derivatives, and other compound classes with 89 Zr in both clinical and pre-clinical settings, there is an urgent need to acquire valuable recommendations and guidelines towards standardization of labeling procedures. Main body This review provides an overview of the key aspects of 89 Zr-radiochemistry and radiopharmaceuticals. Production of 89 Zr, conjugation with the mostly used chelators and radiolabeling strategies, and quality control of the radiolabeled products are described in detail, together with discussions about alternative options and critical steps, as well as recommendations for troubleshooting. Moreover, some historical background on 89 Zr-immuno-PET, coordination chemistry of 89 Zr, and future perspectives are provided. This review aims to serve as a quick-start guide ...